4th Quarter - Report

ABBVIE, INC. for ABBVIE INC.

Firm
Client
Income
—
Expenses
$650,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 1425, Patient Protection and Affordable Care Enhancement Act - provisions relating to pharmaceutical price controls H.R.6383, Uterine Fibroid Research and Education Act of 2020 H.R.7647, To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage 340B drug discount program policy issues Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans proposed rule

LobbyistCovered position, as disclosed
DANIEL BACHNER —
BINTA BEARD —
STEPHEN SCANGO —

Contacted: HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Natl Economic Council (NEC); Council of Economic Advisers (CEA)

Bills named: H.R. 7647 (116th), H.R. 1425 (116th), H.R. 6383 (116th)

Copyright/Patent/Trademark CPT

H.R.5133, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 S.1416, Affordable Prescriptions for Patients Act of 2019 Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property

LobbyistCovered position, as disclosed
DORCAS ADEKUNLE New Legislative Assistant (1/2015-9/2015), Senior Counsel (9/2015-5/2017) and Chief Counsel (5/2017-12/2018) for Representative Bonnie Watson Coleman; Legislative Director and Deputy Chief of Staff (1/2019-11/2020) for Representative Susan Wild
DANIEL BACHNER —
BINTA BEARD —
STEPHEN SCANGO —

Contacted: Commerce, Dept of (DOC); Treasury, Dept of; SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Natl Economic Council (NEC); Council of Economic Advisers (CEA)

Bills named: H.R. 5133 (116th), S. 1416 (116th)

Budget/Appropriations BUD

H.R. 133, Consolidated Appropriations Act, 2021 - Provisions relating to pharmaceuticals

LobbyistCovered position, as disclosed
DANIEL BACHNER —
BINTA BEARD —
STEPHEN SCANGO —

Contacted: U.S. Trade Representative (USTR); Natl Economic Council (NEC); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Council of Economic Advisers (CEA); Commerce, Dept of (DOC)

Bills named: H.R. 133 (116th)

Trade (domestic/foreign) TRD

Policy proposals impacting biopharmaceutical supply chain USITC 337 review

LobbyistCovered position, as disclosed
DANIEL BACHNER —
STEPHEN SCANGO —

Contacted: Council of Economic Advisers (CEA); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; Natl Economic Council (NEC); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Treasury, Dept of

Medicare/Medicaid MMM

H.R. 19, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions S. 1895, Lower Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues S. 2543, Prescription Drug Pricing Reduction Act of 2019 - Provisions related to Medicare Part D, Medicaid, and drug pricing S. 2911, Seniors Prescription Drug Relief Act of 2019 - Provisions related to Medicare Part D and Medicaid rebates S. 3129, Lower Costs, More Cures Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions Executive Order 13948, White House Executive Order on Lowering Drug Prices by Putting America First Executive Order 13939, White House Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements (CMS 2482-F) CMS Most Favored Nation (MFN) Model interim final rule (MFN Rule), implementing President Trump's proposal to align drug prices in the United States with those available in economically similar countries

LobbyistCovered position, as disclosed
DANIEL BACHNER —
BINTA BEARD —
STEPHEN SCANGO —

Contacted: Natl Economic Council (NEC); Council of Economic Advisers (CEA); Treasury, Dept of; SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Bills named: S. 2543 (116th), S. 1895 (116th), H.R. 19 (116th), S. 2911 (116th), S. 3129 (116th)

Taxation/Internal Revenue Code TAX

Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program

LobbyistCovered position, as disclosed
DORCAS ADEKUNLE New Legislative Assistant (1/2015-9/2015), Senior Counsel (9/2015-5/2017) and Chief Counsel (5/2017-12/2018) for Representative Bonnie Watson Coleman; Legislative Director and Deputy Chief of Staff (1/2019-11/2020) for Representative Susan Wild
DANIEL BACHNER —
STEPHEN SCANGO —

Contacted: Natl Economic Council (NEC); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; Health & Human Services, Dept of (HHS); Treasury, Dept of; Commerce, Dept of (DOC); Council of Economic Advisers (CEA)

Bills named: H.R. 1 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.